Press releaseBusiness Wire
Zivo Bioscience
ZIVO · OTC
$6.80+$0.30 (+4.62%)TodayMarket closed ·
Prev close $6.50
Latest news
- Press releaseBusiness Wire
ZIVO Bioscience Provides Special Letter to Shareholders
- Press releaseBusiness Wire
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
- Press releaseBusiness Wire
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
- Press releaseBusiness Wire
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
- Press releaseBusiness Wire
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
- Press releaseBusiness Wire
ZIVO Bioscience to Present at The Microcap Conference 2025
- Press releaseBusiness Wire
ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities
- Press releaseBusiness Wire
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
- Press releaseBusiness Wire
ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.